Skin Gene Expression Profiles in Systemic Sclerosis: From Clinical Stratification to Precision Medicine

Systemic sclerosis, also known as scleroderma or SSc, is a condition characterized by significant heterogeneity in clinical presentation, disease progression, and response to treatment. Consequently, the design of clinical trials to successfully identify effective therapeutic interventions poses a major challenge. Recent advancements in skin molecular profiling technologies and stratification techniques have enabled the identification of patient subgroups that may be relevant for personalized treatment approaches. This narrative review aims at providing an overview of the current status of skin gene expression analysis using computational biology approaches and highlights the benefits of stratifying patients upon their skin gene signatures. Such stratification has the potential to lead toward a precision medicine approach in the management of SSc.

[1]  J. D. de Vries-Bouwstra,et al.  Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database. , 2023, JAMA dermatology.

[2]  John Nguyen,et al.  Tripterygium wilfordii derivative celastrol, a YAP inhibitor, has antifibrotic effects in systemic sclerosis , 2023, Annals of the Rheumatic Diseases.

[3]  A. Yoshizaki,et al.  Impact of guselkumab on three cases of SSc accompanying psoriasis. , 2023, Rheumatology.

[4]  R. Lafyatis,et al.  Single-Cell Transcriptome Analysis Identifies Subclusters with Inflammatory Fibroblast Responses in Localized Scleroderma , 2023, International journal of molecular sciences.

[5]  H. Sumida,et al.  Interleukin-17 pathway inhibition with brodalumab in early systemic sclerosis: analysis of a single-arm, open-label, phase 1 trial. , 2023, Journal of the American Academy of Dermatology.

[6]  D. Rimar,et al.  Differentially expressed genes in systemic sclerosis: Towards predictive medicine with new molecular tools for clinicians. , 2023, Autoimmunity reviews.

[7]  M. Boubaya,et al.  Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort. , 2022, The Lancet. Rheumatology.

[8]  L. Tsoi,et al.  Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial , 2022, JCI insight.

[9]  J. Guthridge,et al.  The promise of precision medicine in rheumatology , 2022, Nature Medicine.

[10]  Tammara A. Wood,et al.  A Genomic Meta-Analysis of Clinical Variables and Their Association with Intrinsic Molecular Subsets in Systemic Sclerosis. , 2022, Rheumatology.

[11]  P. Lipsky,et al.  Machine learning reveals distinct gene signature profiles in lesional and nonlesional regions of inflammatory skin diseases , 2022, Science advances.

[12]  S. Svegliati,et al.  PDGF/PDGFR: A Possible Molecular Target in Scleroderma Fibrosis , 2022, International journal of molecular sciences.

[13]  M. Mayes,et al.  Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time , 2021, Annals of the Rheumatic Diseases.

[14]  L. Brogelli,et al.  How do systemic sclerosis manifestations influence patients’ lives? Results from a survey on patients and caregivers , 2021, Current medical research and opinion.

[15]  Wei Chen,et al.  Transcriptomic Evaluation of Juvenile Localized Scleroderma Skin With Histologic and Clinical Correlation , 2021, Arthritis & rheumatology.

[16]  Andrea C. Kakouri,et al.  Fibrotic expression profile analysis reveals repurposed drugs with potential anti-fibrotic mode of action , 2021, PloS one.

[17]  A. Barton,et al.  Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes , 2021, Annals of the Rheumatic Diseases.

[18]  Tammara A. Wood,et al.  Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement , 2020, Annals of the Rheumatic Diseases.

[19]  A. Iagnocco,et al.  Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. , 2020, Autoimmunity reviews.

[20]  Ami A. Shah,et al.  Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile , 2019, Annals of the rheumatic diseases.

[21]  Howard Y. Chang,et al.  GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways , 2019, Nature Communications.

[22]  Viktor Martyanov,et al.  A Machine Learning Classifier for Assigning Individual Patients With Systemic Sclerosis to Intrinsic Molecular Subsets , 2019, Arthritis & rheumatology.

[23]  S. Walsh,et al.  Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. , 2019, The New England journal of medicine.

[24]  D. Furst,et al.  OP0065 THE VERY EARLY DIAGNOSIS OF SYSTEMIC SCLEROSIS (VEDOSS) PROJECT: PREDICTORS TO DEVELOP DEFINITE DISEASE FROM AN INTERNATIONAL MULTICENTRE STUDY , 2019, Oral Presentations.

[25]  G. Raghu,et al.  Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. , 2019, The New England journal of medicine.

[26]  I. Tagkopoulos,et al.  Compendium of skin molecular signatures identifies key pathological features associated with fibrosis in systemic sclerosis , 2019, Annals of the rheumatic diseases.

[27]  W. Marut,et al.  New insights into the genetics and epigenetics of systemic sclerosis , 2018, Nature Reviews Rheumatology.

[28]  Dianxu Ren,et al.  Novel classification for global gene signature model for predicting severity of systemic sclerosis , 2018, PloS one.

[29]  Jaclyn N. Taroni,et al.  Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin. , 2018, The Journal of investigative dermatology.

[30]  Haiyin Chen-Harris,et al.  Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis , 2018, Arthritis & rheumatology.

[31]  Z. Modrušan,et al.  Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis , 2018, Annals of the rheumatic diseases.

[32]  Tammara A. Wood,et al.  Belimumab for the Treatment of Early Diffuse Systemic Sclerosis , 2018, Arthritis & rheumatology.

[33]  C. Henke,et al.  Extracellular matrix as a driver of progressive fibrosis. , 2018, The Journal of clinical investigation.

[34]  T. Krieg,et al.  Pathophysiological Mechanisms in Sclerosing Skin Diseases , 2017, Front. Med..

[35]  Alex Kuo,et al.  Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity. , 2016, JCI insight.

[36]  M. Balaan,et al.  Acute Respiratory Distress Syndrome , 2016, Critical care nursing quarterly.

[37]  M. Baron,et al.  Late Nailfold Videocapillaroscopy Pattern Associated With Hand Calcinosis and Acro‐Osteolysis in Systemic Sclerosis , 2016, Arthritis care & research.

[38]  A. Theocharis,et al.  Extracellular matrix structure. , 2016, Advanced drug delivery reviews.

[39]  Jeffrey T. Chang,et al.  Dissecting the Heterogeneity of Skin Gene Expression Patterns in Systemic Sclerosis , 2015, Arthritis & rheumatology.

[40]  Jane Worthington,et al.  Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway , 2015, Annals of the rheumatic diseases.

[41]  Tammara A. Wood,et al.  Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial , 2015, Arthritis Research & Therapy.

[42]  M. Whitfield,et al.  Gene expression profiling offers insights into the role of innate immune signaling in SSc , 2015, Seminars in Immunopathology.

[43]  C. Chizzolini,et al.  The role of the acquired immune response in systemic sclerosis , 2015, Seminars in Immunopathology.

[44]  M. Whitfield,et al.  Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. , 2015, The Journal of clinical investigation.

[45]  Tammara A. Wood,et al.  Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis , 2015, Arthritis Research & Therapy.

[46]  Viktor Martyanov,et al.  Systems Level Analysis of Systemic Sclerosis Shows a Network of Immune and Profibrotic Pathways Connected with Genetic Polymorphisms , 2015, PLoS Comput. Biol..

[47]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Papillary Thyroid Carcinoma , 2014, Cell.

[48]  Oliver Distler,et al.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. , 2013, Arthritis and rheumatism.

[49]  Tammara A. Wood,et al.  Molecular Signatures in Skin Associated with Clinical Improvement During Mycophenolate Treatment in Systemic Sclerosis , 2013, The Journal of investigative dermatology.

[50]  M. Mayes,et al.  Genetics of scleroderma: implications for personalized medicine? , 2013, BMC Medicine.

[51]  K. Lipson,et al.  CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis , 2012, Fibrogenesis & tissue repair.

[52]  O. Distler,et al.  Molecular targets for therapy in systemic sclerosis , 2012, Fibrogenesis & tissue repair.

[53]  S. Pendergrass,et al.  Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies , 2012, The Journal of investigative dermatology.

[54]  Simon M. Lin,et al.  Egr-1 Induces a Profibrotic Injury/Repair Gene Program Associated with Systemic Sclerosis , 2011, PloS one.

[55]  Teresa M. Przytycka,et al.  Identifying Causal Genes and Dysregulated Pathways in Complex Diseases , 2011, PLoS Comput. Biol..

[56]  Howard Y. Chang,et al.  Molecular framework for response to imatinib mesylate in systemic sclerosis. , 2009, Arthritis and rheumatism.

[57]  S. Pendergrass,et al.  Correction: Molecular Subsets in the Gene Expression Signatures of Scleroderma Skin , 2008, PLoS ONE.

[58]  F. Verrecchia,et al.  Transforming growth factor-β and fibrosis , 2007 .

[59]  T. Krieg,et al.  Skin disease: a cardinal feature of systemic sclerosis. , 2006, Rheumatology.

[60]  David Botstein,et al.  Systemic and cell type-specific gene expression patterns in scleroderma skin , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[61]  C. Denton,et al.  Atlas of Ulcers in Systemic Sclerosis , 2019, Springer International Publishing.

[62]  J. Rosenbloom,et al.  Human Fibrotic Diseases: Current Challenges in Fibrosis Research. , 2017, Methods in molecular biology.

[63]  G. Riemekasten,et al.  [Management of digital ulcers in patients with systemic sclerosis]. , 2012, Deutsche medizinische Wochenschrift.